@article{oai:sapmed.repo.nii.ac.jp:00014135,
 author = {高橋, 弘毅},
 issue = {1-6},
 journal = {札幌医学雑誌 = The Sapporo medical journal, The Sapporo medical journal},
 month = {Dec},
 note = {Interstitial pneumonia (IP) is a general category that includes many different pulmonary conditions based on inflammation and fibrosis in the lung. Idiopathic pulmonary fibrosis (IPF), a subtype of idiopathic interstitial pneumonias (IIPs), is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause. IIPs including IPF became specified as an incurable disease by Japanese Ministry of Health, Labour and Welfare. To clarify the actual situation in their epidemiology, we carried out a large-scale cohort study in Hokkaido. The current status of IPF in Japan was characterized for the first time through our study. Surfactant protein (SP)-A and SP-D which are serologic markers developed by our university-industry research collaboration are adopted in diagnostic criteria for IIPs which the ministry established. In new treatment, Pirfenidone having anti-fibrotic effect was developed and authorized as an orphan drug of IPF by multicentral-clinical trial in which our department took an important role. The use of the new drug will improve prognosis of IPF in the near future.},
 pages = {13--17},
 title = {間質性肺炎とサーファクタント蛋白質},
 volume = {84},
 year = {2015}
}